贝达药业(300558.SZ)：BPI-572270胶囊获得临床试验批准通知书

Core Viewpoint - Beida Pharmaceutical's subsidiary, Hangzhou Jingyao Biotechnology, has received approval from the National Medical Products Administration (NMPA) for clinical trials of BPI-572270 capsules aimed at treating patients with advanced malignant solid tumors [1][2]. Group 1: Company Developments - Beida Pharmaceutical's subsidiary, Hangzhou Jingyao Biotechnology, has been granted a clinical trial approval notice by NMPA for BPI-572270 [1]. - BPI-572270 is a novel compound developed by the company, possessing complete independent intellectual property rights [2]. Group 2: Product Details - BPI-572270 is a new type of potent pan-RAS non-degradable molecular glue inhibitor [2]. - The mechanism of action involves inducing the binding of the chaperone protein Cyclophilin A (CYPA) to activated RAS mutant proteins, leading to conformational changes that prevent RAS from interacting with downstream signaling proteins, thereby blocking tumor growth pathways like MAPK [2]. - Preclinical studies indicate that BPI-572270 effectively inhibits various tumor cells with different RAS mutations, including pancreatic cancer, non-small cell lung cancer, and colorectal cancer, while also demonstrating excellent pharmacokinetic properties and good safety [2]. - The compound shows promise for single-agent treatment of multiple RAS-mutant cancers or for achieving more comprehensive disease control through combination therapy [2].